Enzolytics, Inc. (OTCID: ENZC) ("enzolytics.com”)
(the “Company” or “Enzolytics”) announced today the receiving a Letter of
Support from IQVIA Biotech for seeking a grant to fund the IND-enabling studies
for the Cancer Drug, entitled “The XX Clinical Trials: Therapeutic of Cancer
Indication.” This support includes
non-clinical planning, CMC Planning, Target Product Profile, Clinical
Development through Phase I registration, IND-enabling Gap analysis,
first-in-human study design and synopsis, protocol preparation, IND-Preparation
and submission and IND maintenance.”
Diana Zhabilov,
CEO of Enzolytics says, “We are excited to be working IQVIA and utilizing their
extensive experience in helping sponsors through the IND-Enabling process for
indications of prostate cancer. ENZC
welcomes working with such an amazing company to get our patented cancer
product through the regulatory process.”
About Enzolytics, Inc.
Enzolytics, Inc. is transitioning from solely a drug
development company committed to commercializing its proprietary proteins and
monoclonal antibodies to treat debilitating infectious diseases to include the
additional contracted service areas of sales, marketing and distribution
focusing on medical devices, medical testing and nutraceutical products.
Forward Looking Statements
The disclosure herein includes certain statements that are not historical facts
but are forward-looking statements for purposes of the safe harbor provisions
under the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements generally are accompanied by words such as
“believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,”
“expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,”
“future,” “outlook,” and similar expressions that predict or indicate future
events or trends or that are not statements of historical matters. These
forward-looking statements include, but are not limited to, statements
regarding projections, estimates and forecasts of revenue and other financial
and performance metrics and projections of market opportunity and expectations,
Company’s ability to enter into a definitive business combination agreement and
Company’s ability to obtain the financing necessary to consummate the potential
business combination transaction. These statements are based on various
assumptions and on the current expectations of Company’s management and are not
predictions of actual performance. These forward-looking statements are
provided for illustrative purposes only and are not intended to serve as, and
must not be relied on by any investor as, a guarantee, an assurance, a
prediction or a definitive statement of fact or probability. Actual events and
circumstances are difficult or impossible to predict and will differ from
assumptions. Many actual events and circumstances are beyond the control of
Company. These forward-looking statements are subject to a number of risks and
uncertainties, including: Company’s ability to enter into a definitive
agreement with respect to the proposed business combination or consummate a
transaction; the risk that the approval of the stockholders of Company for the
potential transaction is not obtained; failure to realize the anticipated
benefits of the potential transaction, including as a result of a delay in
consummating the potential transaction or difficulty in integrating the
businesses of Company; the amount of redemption requests made by Company’s
stockholders and the amount of funds remaining in Company’s trust account after
satisfaction of such requests; those factors discussed in Company’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2023 under the
heading “Risk Factors,” and other documents of Company filed, or to be filed,
with the SEC. If the risks materialize or assumptions prove incorrect, actual
results could differ materially from the results implied by these
forward-looking statements. There may be additional risks that Company
presently does not know or that Company currently believes are immaterial that
could also cause actual results to differ from those contained in the
forward-looking statements. In addition, forward-looking statements reflect
Company’s expectations, plans or forecasts of future events and views as of the
date hereof. Company anticipates that subsequent events and developments will
cause Company’s assessments to change. However, while Company may elect to
update these forward-looking statements at some point in the future, Company
specifically disclaims any obligation to do so. These forward-looking
statements should not be relied upon as representing Company’s assessments as
of any date subsequent to the date of this disclosure statement. Accordingly,
undue reliance should not be placed upon the forward-looking statements.
CONTACT INFORMATION
Enzolytics, Inc.
Diana Zhabilov, Chief Executive Officer
1101 Raintree Circle, Suite 130
Allen, Texas 75013
Tel: (845) 925-4597
Translate
